YC-1 [3-(5 '-hydroxymethyl-2 '-furyl)-1-benzyl indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G(0)-G(1) in human hepatocellular carcinoma cells

CMUR > College of Pharmacy > Graduate Institute of Pharmaceutical Chemistry > Journal articles > Item 310903500/31011

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/31011

Title:	YC-1 [3-(5 '-hydroxymethyl-2 '-furyl)-1-benzyl indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G(0)-G(1) in human hepatocellular carcinoma cells
Authors:	Wang, SW;Pan, SL;Guh, JH;Chen, HL;Huang, DM;Chang, YL;Kuo, SC;Lee, FY;Teng, CM
Contributors:	藥學院藥化所;Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei 10764, Taiwan;Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei 10764, Taiwan;Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan;China Med Univ, Grad Inst Pharmaceut Chem, Taichung, Taiwan;Yung Shin Pharmaceut Ind Co Ltd, Taichung, Taiwan
Date:	2005
Issue Date:	2010-09-24 15:09:45 (UTC+8)
Publisher:	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
Abstract:	Object. The author sought to investigate the temporal changes of postsympathectomy compensatory hyperhidrosis and recurrent sweating in patients with primary palmar hyperhidrosis. Methods. The author examined 91 consecutive patients for this prospective 6-year study. The patients were interviewed at least twice during a 6-month interval; the first follow up was conducted at a median of 1.7 years after surgery (range 2.5-60.5 months). Overall, 24 patients (26.4%) were followed for more than 2 years. Attention was focused on patient satisfaction and the incidence of compensatory hyperhidrosis and recurrent sweating. The overall mean patient satisfaction rate was 78%, with a median 80% improvement on a visual analog scale from 0% (poor) to 100% (excellent). Overall, 88 patients (96.7%) developed compensatory hyperhidrosis, with the mean initial occurrence at 8.2 weeks. The symptoms of compensatory hyperhidrosis progressively worsened to the maximum degree within another 2 weeks after onset (mean 10.3 +/- 1.83 weeks). In 19 patients (21.6%), symptoms of compensatory hyperhidrosis improved spontaneously within 3 months after sympathectomy (mean 13.3 weeks). Postoperative compensatory hyperhidrosis occurred in 71.4% of patients within the 1st year. Recurrent sweating occurred in only 17.6% of patients. None of these patients required repeated operation. The earliest onset of recurrent sweating was noted at 2 weeks postoperatively by three patients, and the mean initial postoperative reccurrence was 32.7 weeks after surgery. Conclusions. Compensatory hyperhidrosis and recurrent sweating are normal thermoregulatory responses that occurred after upper thoracic sympathectomy. Compensatory hyperhidrosis was more prevalent and developed earlier than recurrent sweating. The severity of both compensatory hyperhidrosis and recurrent sweating symptoms remained stable 6 months after surgery.
Relation:	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 312(3):917-925
Appears in Collections:	[Graduate Institute of Pharmaceutical Chemistry] Journal articles

Files in This Item:

There are no files associated with this item.

Loading...